Wall Street brokerages predict that REDHILL BIOPHAR/S (NASDAQ:RDHL) will report earnings of ($0.42) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for REDHILL BIOPHAR/S’s earnings, with estimates ranging from ($0.44) to ($0.40). REDHILL BIOPHAR/S posted earnings per share of ($0.90) in the same quarter last year, which would indicate a positive year-over-year growth rate of 53.3%. The company is expected to report its next quarterly earnings results on Monday, November 12th.

According to Zacks, analysts expect that REDHILL BIOPHAR/S will report full year earnings of ($1.75) per share for the current fiscal year, with EPS estimates ranging from ($1.83) to ($1.60). For the next financial year, analysts forecast that the firm will report earnings of ($1.40) per share, with EPS estimates ranging from ($2.10) to ($1.00). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for REDHILL BIOPHAR/S.

RDHL has been the subject of several analyst reports. HC Wainwright set a $36.00 price objective on REDHILL BIOPHAR/S and gave the stock a “buy” rating in a research note on Wednesday, May 9th. LADENBURG THALM/SH SH began coverage on REDHILL BIOPHAR/S in a report on Monday, June 25th. They issued a “buy” rating and a $20.00 target price for the company. Zacks Investment Research raised REDHILL BIOPHAR/S from a “hold” rating to a “buy” rating and set a $6.75 target price for the company in a report on Saturday, May 12th. Finally, ValuEngine lowered REDHILL BIOPHAR/S from a “sell” rating to a “strong sell” rating in a report on Tuesday, May 8th. Two equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $19.96.

Shares of REDHILL BIOPHAR/S stock traded down $0.06 on Friday, hitting $7.45. The company had a trading volume of 1,020 shares, compared to its average volume of 280,460. The company has a market cap of $159.55 million, a PE ratio of -2.81 and a beta of 0.75. REDHILL BIOPHAR/S has a 1 year low of $4.30 and a 1 year high of $11.49.

An institutional investor recently raised its position in REDHILL BIOPHAR/S stock. ARK Investment Management LLC increased its holdings in REDHILL BIOPHAR/S (NASDAQ:RDHL) by 8.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 112,648 shares of the biotechnology company’s stock after acquiring an additional 8,894 shares during the period. ARK Investment Management LLC owned about 0.53% of REDHILL BIOPHAR/S worth $961,000 at the end of the most recent quarter. Institutional investors own 22.50% of the company’s stock.


RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs.

Further Reading: How do investors use RSI to grade stocks?

Get a free copy of the Zacks research report on REDHILL BIOPHAR/S (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.